Literature DB >> 2789432

COOH-terminal-modified interleukin-3 is retained intracellularly and stimulates autocrine growth.

C E Dunbar1, T M Browder, J S Abrams, A W Nienhuis.   

Abstract

Autocrine growth due to dysregulated growth factor production may have a role in the development of neoplasia. Whether autocrine growth is stimulated by growth factor secretion in an autocrine loop or by intracellular binding of the growth factor to a receptor has been unclear. The carboxyl-terminus coding sequence for murine interleukin-3 (IL-3) was extended with an oligonucleotide encoding a four-amino acid endoplasmic reticulum retention signal. IL-3-dependent hematopoietic cells became growth factor-independent when the modified IL-3 gene was introduced by retroviral gene transfer, despite lack of secretion of the modified IL-3. Hence autocrine growth can occur as a result of the intracellular action of a growth factor and this mechanism may be important in neoplastic and normal cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2789432     DOI: 10.1126/science.2789432

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  21 in total

1.  An amino-terminal fragment of the Friend murine leukemia virus envelope glycoprotein binds the ecotropic receptor.

Authors:  J M Heard; O Danos
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  Real-time quantitative measurement of autocrine ligand binding indicates that autocrine loops are spatially localized.

Authors:  D A Lauffenburger; G T Oehrtman; L Walker; H S Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Erythroid progenitors differentiate and mature in response to endogenous erythropoietin.

Authors:  T Sato; T Maekawa; S Watanabe; K Tsuji; T Nakahata
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

4.  Aberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus Macaque.

Authors:  Diego A Espinoza; Xing Fan; Di Yang; Stefan F Cordes; Lauren L Truitt; Katherine R Calvo; Idalia M Yabe; Selami Demirci; Kristin J Hope; So Gun Hong; Allen Krouse; Mark Metzger; Aylin Bonifacino; Rong Lu; Naoya Uchida; John F Tisdale; Xiaolin Wu; Suk See DeRavin; Harry L Malech; Robert E Donahue; Chuanfeng Wu; Cynthia E Dunbar
Journal:  Mol Ther       Date:  2019-04-09       Impact factor: 11.454

5.  Constitutive IL-2 expression in HTLV-I-infected leukaemic T cell lines.

Authors:  J P Farcet; F Lebargy; C Lavignac; P Gaulard; A Dautry; L Gazzolo; P H Roméo; W Vainchenker
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

6.  Premature ligand-receptor interaction during biosynthesis limits the production of growth factor midkine and its receptor LDL receptor-related protein 1.

Authors:  Kazuma Sakamoto; Guojun Bu; Sen Chen; Yoshifumi Takei; Kenji Hibi; Yasuhiro Kodera; Lynn M McCormick; Akimasa Nakao; Masaharu Noda; Takashi Muramatsu; Kenji Kadomatsu
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

7.  Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin.

Authors:  H Weber; D S Taylor; C J Molloy
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

8.  Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro.

Authors:  B Barut; D Chauhan; H Uchiyama; K C Anderson
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

9.  Autocrine stimulation by erythropoietin and autonomous growth of human erythroid leukemic cells in vitro.

Authors:  M T Mitjavila; J P Le Couedic; N Casadevall; S Navarro; J L Villeval; A Dubart; W Vainchenker
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

10.  Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines.

Authors:  Y Levy; A Tsapis; J C Brouet
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.